-
Je něco špatně v tomto záznamu ?
Monitoring of plasma circulating donor DNA reflects cardiac graft injury: Report of two cases
D. Dlouha, P. Huckova, E. Rohlova, J. Vymetalova, S. Novakova, JA. Hubacek
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu kazuistiky
PubMed
38357233
DOI
10.3892/br.2024.1738
Knihovny.cz E-zdroje
- Publikační typ
- kazuistiky MeSH
The current standard for graft rejection surveillance is endomyocardial biopsy (EMB), an invasive procedure with rare but potentially serious complications. Detection of circulating donor-derived cell-free DNA (ddcfDNA) is an option for noninvasive monitoring of graft injury and rejection. A 63-year-old man and a 65-year-old woman were monitored by EMB for allograft rejection. A total of 48 single-nucleotide polymorphisms with a minor allele frequency range of 0.4-0.5 were screened to distinguish donor and recipient DNA based on homozygosity, and digital droplet PCR was used to analyze ddcfDNA concentrations. Both subjects suffered rejection within the first 6 months after transplantation. The maximal ddcfDNA level of 270 copies (cp)/ml during EMB-confirmed acute cellular rejection (ACR; mild grade 1R/2, patient 1), and the maximal concentration of 1,846 cp/ml in the case of EMB-confirmed antibody-mediated rejection (AMR; grade 1+; patient 2), was detected. Individual monitoring of ddcfDNA dynamics from the 1st to the 6th month posttransplant reflected cardiac graft injury in patients suffering ACR or AMR, meaning that ddcfDNA may serve as a noninvasive biomarker.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005681
- 003
- CZ-PrNML
- 005
- 20251211091402.0
- 007
- ta
- 008
- 240405s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/br.2024.1738 $2 doi
- 035 __
- $a (PubMed)38357233
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dlouha, Dana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
- 245 10
- $a Monitoring of plasma circulating donor DNA reflects cardiac graft injury: Report of two cases / $c D. Dlouha, P. Huckova, E. Rohlova, J. Vymetalova, S. Novakova, JA. Hubacek
- 520 9_
- $a The current standard for graft rejection surveillance is endomyocardial biopsy (EMB), an invasive procedure with rare but potentially serious complications. Detection of circulating donor-derived cell-free DNA (ddcfDNA) is an option for noninvasive monitoring of graft injury and rejection. A 63-year-old man and a 65-year-old woman were monitored by EMB for allograft rejection. A total of 48 single-nucleotide polymorphisms with a minor allele frequency range of 0.4-0.5 were screened to distinguish donor and recipient DNA based on homozygosity, and digital droplet PCR was used to analyze ddcfDNA concentrations. Both subjects suffered rejection within the first 6 months after transplantation. The maximal ddcfDNA level of 270 copies (cp)/ml during EMB-confirmed acute cellular rejection (ACR; mild grade 1R/2, patient 1), and the maximal concentration of 1,846 cp/ml in the case of EMB-confirmed antibody-mediated rejection (AMR; grade 1+; patient 2), was detected. Individual monitoring of ddcfDNA dynamics from the 1st to the 6th month posttransplant reflected cardiac graft injury in patients suffering ACR or AMR, meaning that ddcfDNA may serve as a noninvasive biomarker.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Huckova, Pavlina $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
- 700 1_
- $a Rohlová, Eva $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u Laboratory of Gene Expression, Institute of Biotechnology, Czech Academy of Science, BIOCEV, 25250 Vestec, Czech Republic $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, 12808 Prague, Czech Republic $7 xx0338721
- 700 1_
- $a Vymetalova, Jevgenija $u Cardio Center, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
- 700 1_
- $a Novakova, Sarka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
- 700 1_
- $a Hubacek, Jaroslav A $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic
- 773 0_
- $w MED00194296 $t Biomedical reports $x 2049-9442 $g Roč. 20, č. 3 (2024), s. 50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38357233 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20251211091346 $b ABA008
- 999 __
- $a ok $b bmc $g 2075989 $s 1215443
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 20 $c 3 $d 50 $e 20240129 $i 2049-9442 $m Biomedical reports $n Biomed Rep $x MED00194296
- LZP __
- $a Pubmed-20240405
